Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
60–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
In good general health, and postmenopausal for at least 5 years or more
Diagnosed with postmenopausal osteoporosis
Currently taking alendronate for at least 3 years or more for the treatment of osteoporosis
One hip free of orthopedic hardware (ie, total hip device, hip pin); anatomy is suitable to undergo a dual-emission X-ray absorptiometry (DXA) scan (ie, bone mineral density scan)
Agrees to not to use any other medications for the treatment of osteoporosis except those provided to the participant during the study
You may not be if
Evidence of metabolic bone disorder
History of malignancy (cancer) for 5 years or less
Active thyroid disease that cannot be managed with medication
Severe renal insufficiency (kidney disease), myocardial infarction, unstable angina, stroke or revascularization, untreated malabsorption syndrome, and/or osteonecrosis of the jaw, or anticipates undergoing a major dental procedure (e.g. dental extraction or implantation)
Use, misuse, abuse, and/or addiction of illicit drugs and/or recent history
(within the last year) of drug or alcohol abuse or dependence
Use of estrogen with or without progestin and/or raloxifene (ie, Evista®) or tamoxifen (ie, Nolvadex®, Tamofen®)
Use of any oral bisphosphonate therapy other than alendronate; intravenous bisphosphonates (zoledronate, ibandronate, pamidronate); any form of calcitonin other than intranasal; anabolic steroids; and/or Strontium-containing products (ie, Osteovalin™)
Clareo Health | Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)
